Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
Raj K VuppalanchiStephen CaldwellArun J SanyalAmir NikooieYuanyuan TangDeborah A RobinsBram BrouwersMark L HartmanPublished in: Alimentary pharmacology & therapeutics (2024)
For at-risk MASH trials based on liver histology, the implementation of inclusion criteria with the proposed FAST score and AST cut-offs in this trial was most effective at non-specialist sites.